Modified Yeast Host Cells for Isoprenol Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing isoprenol in Saccharomyces cerevisiae result in low titers due to growth inhibition, plasmid instability, and accumulation of toxic intermediates, limiting its commercial viability as a biofuel.
Innovation Solution
A genetically modified yeast host cell is developed by overexpressing specific enzymes and knocking out endogenous genes to utilize the IPP-bypass pathway, enhancing isoprenol production to high titers through optimized fermentation processes and phosphatase overexpression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the MVA pathway is engineered to produce isoprenol in yeast, then isoprenol production is achieved, but growth inhibition and plasmid instability occur due to toxic intermediate accumulation
Solution Approach 1:
The patent converts the harmful accumulation of toxic intermediate (isopentenyl diphosphate) into a beneficial pathway by introducing an engineered decarboxylase that specifically converts this intermediate to isoprenol, thereby eliminating toxicity while maintaining production. This transforms the harmful substance into a useful product pathway.
Solution Approach 2:
The patent introduces an engineered decarboxylase as an intermediary enzyme that mediates the conversion of toxic isopentenyl diphosphate to isoprenol. This intermediary enzyme acts as a bridge to transform the harmful intermediate into a beneficial product, resolving the contradiction between production and cell viability.
2Productivity
If pathway enzymes are overexpressed to increase isoprenol production, then production rate increases, but metabolic homeostasis is disrupted causing growth inhibition
Solution Approach 1:
The patent changes the metabolic parameters by introducing a novel decarboxylase enzyme with specific kinetic properties that operate optimally at different substrate concentrations. This parameter change allows the pathway to function at high production rates without disrupting cellular homeostasis, as the engineered enzyme maintains metabolic balance even under overexpression conditions.
3Quantity of substance
If conventional fermentation processes are used, then process simplicity is maintained, but isoprenol titer remains low due to metabolic limitations
Solution Approach 1:
The patent applies preliminary action by pre-engineering the yeast strain with the novel decarboxylase pathway before fermentation. This genetic modification is performed in advance to establish the metabolic capability for high-titer isoprenol production, allowing conventional fermentation processes to achieve high titers without requiring complex process modifications during actual fermentation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified yeast strain achieves significantly higher isoprenol production, up to 380 mg/L, overcoming previous limitations of low titer and growth inhibition, making it suitable for industrial-scale biofuel production.
Implementation Method 1
phosphomevalonate decarboxylase (PMD or ERG19sc) from S. cerevisiae
Implementation Method 2
a promiscuous phosphatase (AphA)
Implementation Method 3
S. cerevisiae has been widely used in the biotechnology industry as it has inherent safety, industrial robustness, ease of genetic manipulation, and as it is generally regarded as safe (GRAS) for large-scale operation
Data Source
AI summary
The present invention provides for a genetically modified yeast host cell capable of producing elevated levels of 3-methyl-3-butene-1-ol or isoprenol.